'MAGNETIC THALLIUM' FOR MRI OF ISCHEMIC HEART DISEASE

描述(申请人摘要逐字)：第一阶段确认可行性 EVP 1001-1是“磁共振成像(MRI)用的铊”。 结果显示血管强化程度高，心肌梗死迅速 摄取，最佳药代动力学，独特的成像特性和初步的 安全。自第一阶段以来的其他结果表明， 基于EVP 1001-1增强模式的诱发性心肌缺血 在休息和压力条件下。第二阶段将延长这些安全和 临床相关缺血性心脏病(IHD)模型的疗效结果 并优化未来物资的准备工作。完成后，该代理 将为人类发展做好准备。EVP 1001-1优化利用 MRI对IHD的诊断和治疗计划具有强大的潜力， 有可能取代更有限、更昂贵和更具侵入性的测试。 建议的商业应用： 不可用

DESCRIPTION (Applicant's abstract verbatim): Phase I confirmed the feasibility of EVP 1001-1 to be the "thallium for magnetic resonance imaging" (MRI). Results demonstrated high levels of vascular enhancement, rapid myocardial uptake, optimal pharmacokinetics, unique imaging properties and preliminary safety. Additional results since Phase I suggest excellent utility for inducible myocardial ischemia based on enhancement patterns from EVP 1001-1 under rest and stress conditions. Phase II will extend these safety and efficacy results to clinically relevant models of ischemic heart disease (IHD) and optimize the preparation of future supplies. Upon completion, this agent will be ready for human development. EVP 1001-1 makes optimal use of the powerful potential of MRI for the diagnosis and treatment planning of IHD, with the potential to replace more limited, costly and invasive tests. PROPOSED COMMERCIAL APPLICATION: Not Available